[HTML][HTML] A review of the management of elderly patients with non-small-cell lung cancer
R Blanco, I Maestu, MG de La Torre, A Cassinello… - Annals of …, 2015 - Elsevier
The elderly make up the majority of non-small-cell lung cancer (NSCLC) patients, but there
is a lack of specific evidence to guide treatment; guidelines exist but elderly specific trials are …
is a lack of specific evidence to guide treatment; guidelines exist but elderly specific trials are …
Targeted therapy for older patients with non-small cell lung cancer: Systematic review and guidelines from the French Society of Geriatric Oncology (SoFOG) and the …
L Greillier, M Gauvrit, E Paillaud, N Girard, C Montégut… - Cancers, 2022 - mdpi.com
Simple Summary Targeted therapy has become essential in the treatment of non-small cell
lung cancer (NSCLC). There are currently no guidelines for older patients who are frailer …
lung cancer (NSCLC). There are currently no guidelines for older patients who are frailer …
Treatment of elderly patients with non–small-cell lung cancer: results of an international expert panel meeting of the Italian Association of Thoracic Oncology
C Gridelli, L Balducci, F Ciardiello, M Di Maio… - Clinical Lung Cancer, 2015 - Elsevier
Most patients with non–small-cell lung cancer (NSCLC) are elderly, and age has important
implications for their management and treatment. In May 2014, the Italian Association of …
implications for their management and treatment. In May 2014, the Italian Association of …
Assessment of the external validity of the National Comprehensive Cancer Network and European Society for Medical Oncology guidelines for non–small-cell lung …
NML Battisti, M Sehovic, M Extermann - Clinical Lung Cancer, 2017 - Elsevier
Non–small-cell lung cancer (NSCLC) is a disease of the elderly, who are under-represented
in clinical trials. This challenges the external validity of the evidence base for its …
in clinical trials. This challenges the external validity of the evidence base for its …
[HTML][HTML] Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non …
E Quoix, C Audigier-Valette, A Lavolé… - European Journal of …, 2020 - Elsevier
Purpose Maintenance chemotherapy is a reasonable choice for patients with metastatic non–
small cell lung carcinoma (NSCLC) not progressing after induction therapy with a platinum …
small cell lung carcinoma (NSCLC) not progressing after induction therapy with a platinum …
Current challenges of lung cancer care in an aging population
PC Sacco, F Casaluce, A Sgambato… - Expert Review of …, 2015 - Taylor & Francis
Lung cancer is the most common cancer in the elderly with a high mortality rate. Despite the
high incidence, the elderly are under-represented in clinical trials and under-treated in …
high incidence, the elderly are under-represented in clinical trials and under-treated in …
Erlotinib salvage therapy in pulmonary adenocarcinoma patients with disease progression after previous EGFR-TKI treatment
WS Wu, CH Wu, SL Lai, CH Chiu, JF Shih… - American Journal of …, 2016 - journals.lww.com
Background: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) with promising efficacy in treating pulmonary adenocarcinoma. Treatment …
inhibitor (TKI) with promising efficacy in treating pulmonary adenocarcinoma. Treatment …
Lung Cancer in Older Adults: Systemic Treatment
E Quoix - Geriatric Oncology, 2020 - Springer
Lung cancer is the first cause of death by cancer throughout the entire world. Its incidence
increases with age, and thus median age at diagnosis is 70 years in the USA. As in younger …
increases with age, and thus median age at diagnosis is 70 years in the USA. As in younger …
Estudio exploratorio de evaluación de fragilidad en poblacion con cáncer y edad avanzada (elderly)
AJ Arroyo Salgado - 2017 - dspace.umh.es
El paciente mayor de 70 años con diagnóstico de cáncer presenta, en muchos casos
fragilidad, polifarmacia, comorbilidades y situaciones físicas-emocionales que se tienen que …
fragilidad, polifarmacia, comorbilidades y situaciones físicas-emocionales que se tienen que …